Cargando…

Abstract 141: CGM-based measurements for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-treated patients with type 2 diabetes: A post hoc analysis

Insulin icodec (icodec) is a once-weekly basal insulin in clinical development. In a phase 2 treat-to-target trial in patients with type 2 diabetes (T2D) switching from daily insulin (N = 154), icodec with an initial 100% loading dose (LD; doubling the first dose) showed greater time in range (TIR,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chandrappa, Manu, Bajaj, H S, Bang, R Beck, Gowda, A, Liu1, L, Senior2, P, Bergenstal, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Abstracts … Esicon 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067795/ http://dx.doi.org/10.4103/2230-8210.342266

Ejemplares similares

Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D
por: Kunder, Sushil, et al.
Publicado: (2022)

Abstract 5: Similar hypoglycemia duration with once-weekly insulin icodec versus insulin glargine U100 in insulin naïve or experienced patients with T2D
por: Manjunath, Aparna, et al.
Publicado: (2022)

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
por: Bajaj, Harpreet S., et al.
Publicado: (2021)

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Abstract 21: The burden of mealtime insulin dosing in adults and children with type 1 diabetes
por: Revanna, Manjunatha, et al.
Publicado: (2022)

Abstract 17: Spontaneous hypoglycaemia due to insulin autoimmune syndrome in five cases, response to steroid therapy and rituximab
por: Batra, C M, et al.
Publicado: (2022)

Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials
por: Silva, Rodrigo Ribeiro e, et al.
Publicado: (2023)

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing
por: Nishimura, Erica, et al.
Publicado: (2021)

Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial
por: Pieber, Thomas R., et al.
Publicado: (2023)

Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2022)

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
por: Rahman, Syed Kasfur, et al.
Publicado: (2022)

Abstract 160: A tri prong approach in the management of insulin autoimmune syndrome
por: Kumar, N S Praveen, et al.
Publicado: (2022)

Abstract 44: Persons living with diabetes in India – Their experiences and expectations from the physician
por: Selvan, Chitra, et al.
Publicado: (2022)

Abstract 66: Spectrum of sleep abnormalities in primary hypothyroidism
por: Acharya, Himamshu, et al.
Publicado: (2022)

Abstract 28: Change in glycaemic parameters in adults with type 2 diabetes initiated with or switched to insulin degludec/insulin aspart (IDegAsp) in a real-world setting – An analysis of Indian cohort of ARISE study
por: Baruah, Manash P, et al.
Publicado: (2022)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

Abstract 72: Prevalence, course, and predictive factors of water and electrolyte disturbances (WEDs) following transsphenoidal pituitary surgery (TSS) in patients with pituitary adenoma
por: Bhardwaj, S, et al.
Publicado: (2022)

Abstract 49: Insulin resistance syndrome presenting with diabetic ketoacidosis – A rare case presentation
por: Kaur, Kirandeep, et al.
Publicado: (2022)

Abstract 123: Insulin resistance syndrome presenting with diabetic ketoacidosis – A rare case presentation
por: Kaur, Kirandeep, et al.
Publicado: (2022)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Abstract 16: Urinary metabolic signatures for differential diagnosis of diabetic and non-diabetic kidney disease
por: Basu, Madhurima, et al.
Publicado: (2022)

Abstract 84: Clinical and aetiological spectrum of thyrotoxic patients: A multi-centre analysis
por: Aggarwal, Ajay, et al.
Publicado: (2022)

Abstract 1: Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Abstract 120: Prevalence of hypogonadism in men with type 2 diabetes mellitus and its association with insulin resistance, metabolic and clinical parameters
por: Singh, Jaspreet, et al.
Publicado: (2022)

Abstract 7: Use of growth hormone therapy in short patients born small for gestational age: Data from real-life French clinical practice
por: Paulose, Rinz, et al.
Publicado: (2022)

Abstract 6: Maternal efficacy, safety, and pregnancy outcomes with degludec versus detemir in the treatment of pregnant women with type 1 diabetes: An international, multicentre, randomised trial
por: Balaji, Kamaleswari, et al.
Publicado: (2022)

Abstract 153: Bone microarchitecture, bone mineral density and bone turnover in association with glycemia and insulin action in women with prior gestational diabetes
por: Kubihal, Suraj, et al.
Publicado: (2022)

Abstract 119: Management of newly diagnosed type 2 diabetes mellitus with HBA1C > 10% in patients reluctant to take insulin
por: Panikar, Krish, et al.
Publicado: (2022)

Abstract 58: Favourable outcomes with therapeutic glucocorticoid regimen compared to replacement glucocorticoid regimen in primary hypophysitis
por: Das, Liza, et al.
Publicado: (2022)

Abstract 92: Contemporaneous association of pheochromocytoma with Cushing's syndrome
por: Acharya, Himamshu, et al.
Publicado: (2022)

Abstract 2: Effectiveness and safety of early growth hormone treatment in children born small for gestational age: Long-term data from NordiNet® International Outcome Study (IOS) and ANSWER program
por: Ranjan, K M, et al.
Publicado: (2022)

Abstract 67: Oral: Plantar temperature and pressure distribution in subjects with diabetes mellitus and chronic charcot arthropathy – A case control study
por: Paul, Jinson, et al.
Publicado: (2022)

Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study
por: Kumar, S., et al.
Publicado: (2016)

Abstract 43: Prevalence of islet-autoantibodies and monogenic diabetes in children with recent onset type 1 diabetes mellitus: A multicenter study
por: Jayakrishnan, C, et al.
Publicado: (2022)

Abstract 63: A case report of friedreich ataxia (FA) associated with diabetes mellitus and hypertrophic cardiomyopathy “A tri prong approach in the management of insulin autoimmune syndrome”
por: Kumar, N S Praveen, et al.
Publicado: (2022)

Abstract 62: Relative contribution of insulin resistance and beta cell dysfunction in subjects with metabolic syndrome and new onset diabetes, as assessed by HOMA 2: A comparative analysis from a South Indian cohort
Publicado: (2022)

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Abstract 41: Effect of zoledronic acid on bone mineral density in Indian postmenopausal osteoporotic women with and without diabetes – A prospective cohort study
por: Merugu, Chandhana, et al.
Publicado: (2022)

Abstract 76: Alteration in bone metabolism and bone mineral density with chronic anti-epileptic drug therapy in North Indian population
por: Ashraf, Hamid, et al.
Publicado: (2022)

Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
por: Shabeer, D, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mtkni1hdcmhd15gmk2nameceib